Alternative Data News and Insight

All news

Alternative Data for Healthcare Investors (Part III): Clinical Trial Datasets

Following on from Part II in our healthcare series, which explored the application of machine-learning models to generate phase transition and approval predictions, we provide our view on the alternative datasets that pharma and biotech investors can use to augment their R&D pipeline analysis.


First, for those who are unfamiliar with this topic – clinical trial registration refers to the publication of a formal record of a clinical trial. A trial should be registered by its sponsor (or principal investigator) at or before the time of first patient enrolment. To do so, the sponsor must submit information to a clinical trial registry (e.g. or The EU Clinical Trials Register) about the design, conduct, and administration of the trial. Each registry then stores this information in a publicly accessible database.

Trial registration is a regulatory requirement in some countries (including the US and EU member states) and ‘strongly encouraged’ in others. An additional incentive to register trials comes from the growing number of medical journals refusing to publish the results of trials that were not registered on time (a result of

Request a Neudata trial

We'd like to know a bit more about you and your business, so we can deal with your request efficiently.
We take your privacy seriously and handle your personal data in line with our privacy statement.

We use your email address as part of allowing you access to your account and in order to provide you details with our products that might be of interest to you

Analyst Contact

Annabelle Mamphey Analyst (London)